ClinConnect ClinConnect Logo
Search / Trial NCT05570903

A Prospective Observational Cohort Study of Awake Prone Position Ventilation Strategy in Patients With Acute Respiratory Failure

Launched by FIRST AFFILIATED HOSPITAL OF ZHEJIANG UNIVERSITY · Oct 6, 2022

Trial Information

Current as of August 22, 2025

Not yet recruiting

Keywords

ClinConnect Summary

This clinical trial is studying a technique called "awake prone positioning" for patients with acute respiratory failure. This method involves having patients lie on their stomach while they are awake, which some research suggests might help improve breathing and reduce the need for more invasive treatments like intubation. The trial aims to see if this approach can lead to better outcomes for patients who are experiencing respiratory failure due to various causes, not just COVID-19.

To participate in the study, patients need to be at least 17 years old and admitted to the Intensive Care Unit (ICU) with specific breathing difficulties, such as very low oxygen levels or high carbon dioxide levels. However, those who are very unstable or need immediate intubation, among other conditions, would not be eligible. Participants can expect to receive close monitoring and care while being positioned on their stomach, and the study will compare their results with those receiving standard treatment. This trial is important because it could help improve care strategies for patients with acute respiratory issues.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1.Older than 17 years, admitted to the ICU;2.Patients with acute respiratory failure meet the following conditions:①Under the condition of breathing air at rest, PaO2 of subjects is lower than 60mmHg and/or PaCO2 is higher than 50mmHg; ②Under the support of COT and HFNC, PaO2/FiO2 of the subject is less than 250; ③ Under the support of NIV ;
  • Exclusion Criteria:
  • 1.Refusing to cooperate with active treatment; 2.Immediate need for intubation as determined by the treating team.3Patients with hemodynamic instability and moderate to high dose of vasopressors (norepinephrine dose ≥ 0.15 mcg/kg/min);4.Contraindication to PP (e.g. vomiting, abdominal wound, unstable pelvic/spinal lesions, pregnancy \>20/40 gestation, severe brain injury);

About First Affiliated Hospital Of Zhejiang University

The First Affiliated Hospital of Zhejiang University is a leading medical institution located in Hangzhou, China, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As a prominent sponsor of clinical trials, the hospital leverages its extensive network of specialists and state-of-the-art facilities to facilitate groundbreaking studies across various medical disciplines. With a focus on improving patient outcomes and contributing to global medical knowledge, the hospital actively engages in collaborative research initiatives, ensuring rigorous adherence to ethical standards and regulatory compliance. Its dedication to fostering a culture of scientific inquiry underscores its role as a pivotal player in the advancement of medical science and patient care.

Locations

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials